menu
    • menu
    [{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HDM1002","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huadong Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Huadong Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"SynerK PharmaTech","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"SNK-2726","moa":"Angiotensin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huadong Medicine \/ SynerK PharmaTech","highestDevelopmentStatusID":"4","companyTruncated":"Huadong Medicine \/ SynerK PharmaTech"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein-protein interaction","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Huadong Medicine \/ Insilico Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Huadong Medicine \/ Insilico Medicine"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Huadong Medicine \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Huadong Medicine \/ Exscientia"}]

    Find Clinical Drug Pipeline Developments & Deals by Huadong Medicine

    Menu

    Huadong Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Huadong Medicine

                            China arrow
                            RDD 2025
                            Not Confirmed

                            Huadong Medicine

                            China arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNK-2726

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : SynerK PharmaTech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Huadong and SynerK Partner to Develop siRNA Drug SNK-2726 for Novel Applications

                            Details : Through the collaboration, the two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, which targets angiotensinogen (AGT) for the treatment of hypertension.

                            Product Name : SNK-2726

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            December 30, 2024

                            Lead Product(s) : SNK-2726

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : SynerK PharmaTech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Huadong Medicine

                            China arrow
                            RDD 2025
                            Not Confirmed

                            Huadong Medicine

                            China arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDM1002

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HUADONG MEDICINE Reports Positive Phase I Results for GLP-1 Agonist HDM1002

                            Details : HDM1002 is an innovative potent small molecule drug, highly selective full agonist of the GLP-1 receptor. It is being developed for Type 2 Diabetes Mellitus.

                            Product Name : HDM1002

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 26, 2024

                            Lead Product(s) : HDM1002

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Huadong Medicine

                            China arrow
                            RDD 2025
                            Not Confirmed

                            Huadong Medicine

                            China arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Insilico Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Huadong Medicine and Insilico Medicine Enter Co-Development Partnership to Advance Oncology Drug Discovery by ...

                            Details : The collaboration will leverage Huadong Medicine's advanced innovative drug discovery and screening characterization platform, in combination with Insilico's end-to-end AI-driven drug discovery platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 09, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Insilico Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Huadong Medicine

                            China arrow
                            RDD 2025
                            Not Confirmed

                            Huadong Medicine

                            China arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Exscientia

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Huadong Medicine and Exscientia Enter Co-Development Partnership to Accelerate Oncology Drug Discovery Through...

                            Details : Under this collaboration, Exscientia will use its advanced Centaur Chemist AI platform to design new molecules against project specific targets and Huadong will apply its experimental and managerial capabilities to support Exscientia’s AI design in a r...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 09, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Exscientia

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth